SEC Comment Letter 0000000000-22-013215 to Carisma Therapeutics Inc. (CARM) (CIK 0001485003) (CARM)
Carisma Therapeutics Inc. (CARM) (CIK 0001485003)
Date: Dec. 7, 2022 · CIK: 0001485003 · Accession: 0000000000-22-013215
AI Filing Summary & Sentiment
File numbers found in text: 001-36296
Letter
United States securities and exchange commission logo December 7, 2022 Monica Forbes Chief Financial Officer Sesen Bio, Inc. 245 First Street, Suite 1800 Cambridge, MA 02142
Re: Sesen Bio, Inc. Form 10-K for the period ended December 31, 2021 Filed February 28, Form 10-Q for the period ended September 30, 2022 Filed November 7, File No. 001-36296
Dear Monica Forbes:
We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo
December 7, 2022
Monica Forbes
Chief Financial Officer
Sesen Bio, Inc.
245 First Street, Suite 1800
Cambridge, MA 02142
Re: Sesen Bio, Inc.
Form 10-K for the
period ended December 31, 2021
Filed February 28,
2022
Form 10-Q for the
period ended September 30, 2022
Filed November 7,
2022
File No. 001-36296
Dear Monica Forbes:
We have completed our review of your filings. We remind you that
the company and its
management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
</TEXT>
</DOCUMENT>